EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

K Ray Chaudhuri, Bruno Bergmans iD, Eric Freire-Alvarez, Lucie Hopes, Drew S Kern, Robert S Kirsner, Giulia Lazzeri iD, Pedro Mendes-Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska-Domaszewicz, Rajesh Pahwa und 9 weitere

Movement Disorders Clinical Practice · 2026-07 · 13 (7) · 1601-1611

DOI: 10.1002/mdc3.70489 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 16.01.2026. Verfasst von K Ray Chaudhuri und 20 weiteren Autor:innen. Beteiligte Einrichtung: PDNMG, King's College Hospital London, Dubai, United Arab Emirates. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Levodopa, Carbidopa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been widely utilized since becoming commercially available.

Objectives

To provide practical guidance for clinicians on the real‐world use of LDp/CDp, including information on patient selection, treatment initiation, dose adjustments, and long‐term management.

Methods

This narrative review included investigator experience from studies of LDp/CDp and insights from clinicians with real‐world experience with LDp/CDp, addressing many critical questions that clinicians may have when initiating and managing patients on therapy.

Results

Continuous 24‐h infusion enables consistent, individualized symptom control, with improvements in motor fluctuations and quality of life. LDp/CDp therapy can be initiated, adjusted, and maintained in outpatient settings without hospitalization. While infusion site events are common, they are typically mild to moderate and manageable. Early detection and intervention are important for managing infusion site events. Systemic adverse events associated with dopaminergic therapies (eg, psychosis, hallucinations, nightmares), may require infusion rate adjustment, particularly at night. Setting clear expectations is key to successful therapy adoption and maintenance. It is essential to educate patients, care partners, and clinical teams.

Conclusions

LDp/CDp is a new treatment option for advanced PD (aPD). Treatment success depends on education, selecting appropriate patients, setting patient expectations, implementing individualized dosing strategies, and managing adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseAntiparkinson AgentsLevodopaCarbidopaHumansDrug CombinationsInfusions, Subcutaneous

Stichwörter der Autor:innen

advanced Parkinson's diseasefoslevodopa/foscarbidopasubcutaneous infusion

Substanzen

Antiparkinson AgentsLevodopaCarbidopaDrug Combinations

Autor:innen und Institutionen

  • PDNMG, King's College Hospital London, Dubai, United Arab Emirates.
  • PDNMG, King's College Hospital, London, UK.
  • Dementech Clinical Neuroscience Centre, London, UK.
  • Department of Neurology, AZ St-Jan Brugge, Bruges, Belgium.
  • Department of Neurology, Ghent University Hospital, Ghent, Belgium.
  • Department of Neurology, Movement Disorders Unit, Hospital General Universitario of Elche, Elche, Spain.

ORCID-Profile: Bruno Bergmans, Giulia Lazzeri, Yuval Ramot

Förderung

  • AbbVie

Zitieren

APA

Chaudhuri, K. R., Bergmans, B., Freire-Alvarez, E., Hopes, L., Kern, D. S., Kirsner, R. S., Lazzeri, G., Mendes-Bastos, P., Nishikawa, N., Odin, P., Poplawska-Domaszewicz, K., Pahwa, R., Ramot, Y., Seppi, K., Warnecke, T., Wiggins, R., Shah, M. B., Kukreja, P., Fritz, B., …, & Isaacson, S. H. (2026). Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease. Movement Disorders Clinical Practice, 13(7), 1601-1611. https://doi.org/10.1002/mdc3.70489

Vancouver

Chaudhuri KR, Bergmans B, Freire-Alvarez E, Hopes L, Kern DS, Kirsner RS, et al. Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease. Movement Disorders Clinical Practice. 2026;13(7):1601-1611. doi:10.1002/mdc3.70489

BibTeX
@article{Chaudhuri2026,
  author = {Chaudhuri, K Ray and Bergmans, Bruno and Freire-Alvarez, Eric and Hopes, Lucie and Kern, Drew S and Kirsner, Robert S and Lazzeri, Giulia and Mendes-Bastos, Pedro and Nishikawa, Noriko and Odin, Per and Poplawska-Domaszewicz, Karolina and Pahwa, Rajesh and Ramot, Yuval and Seppi, Klaus and Warnecke, Tobias and Wiggins, Robert and Shah, Megha B and Kukreja, Pavnit and Fritz, Bjoern and Onuk, Koray and Isaacson, Stuart H},
  title = {Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  volume = {13},
  number = {7},
  pages = {1601--1611},
  doi = {10.1002/mdc3.70489}
}
Kostenlos starten →